- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting replication stress in cancer therapy
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-10-07
DOI
10.1038/s41573-022-00558-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An mRNA expression-based signature for oncogene-induced replication-stress
- (2022) Sergi Guerrero Llobet et al. ONCOGENE
- CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
- (2022) David Gallo et al. NATURE
- Preclinical evaluation and Phase 1b study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K/mTOR inhibitor
- (2021) David S. Hong et al. CLINICAL CANCER RESEARCH
- Targeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability
- (2021) Sumeet Nayak et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2021) Stephanie Lheureux et al. LANCET
- Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells
- (2021) Joanne Wayne et al. FEBS Journal
- Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
- (2021) Joyce F. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
- (2021) Shenlan Mao et al. MOLECULAR CANCER THERAPEUTICS
- To skip or not to skip: choosing repriming to tolerate DNA damage
- (2021) Annabel Quinet et al. MOLECULAR CELL
- Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
- (2021) Tara Al Zubaidi et al. Scientific Reports
- The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
- (2021) Stijn Moens et al. Scientific Reports
- Human Papillomavirus and Cellular Pathways: Hits and Targets
- (2021) Alessandro Medda et al. Pathogens
- Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors
- (2021) Khanh T. Do et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer
- (2021) Seung Tae Kim et al. CLINICAL CANCER RESEARCH
- Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
- (2021) Naoko Takebe et al. CLINICAL CANCER RESEARCH
- USP13 regulates the replication stress response by deubiquitinating TopBP1
- (2021) Wootae Kim et al. DNA REPAIR
- Interfaces between cellular responses to DNA damage and cancer immunotherapy
- (2021) Domenic Pilger et al. GENES & DEVELOPMENT
- ARID1A regulates R-loop associated DNA replication stress
- (2021) Shuhe Tsai et al. PLoS Genetics
- Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration
- (2021) Xian Chen et al. Cancers
- 512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies
- (2021) R. Aggarwal et al. ANNALS OF ONCOLOGY
- Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
- (2021) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
- (2021) Zhe Tang et al. CLINICAL CANCER RESEARCH
- EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.
- (2021) Shannon Neville Westin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.
- (2021) Minsuk Kwon et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
- (2021) Stephanie L. Wethington et al. JOURNAL OF CLINICAL ONCOLOGY
- A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
- (2021) Panagiotis A. Konstantinopoulos et al. Nature Communications
- Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
- (2021) Kathleen N. Moore et al. CLINICAL CANCER RESEARCH
- Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
- (2021) Dan Yan et al. Cancers
- SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models
- (2020) Yemin Wang et al. Annual Review of Pathology-Mechanisms of Disease
- Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
- (2020) Alexander Y. Deneka et al. Cancers
- Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
- (2020) Brian T. Burgess et al. Diagnostics
- AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer
- (2020) Nellie K McDaniel et al. CLINICAL CANCER RESEARCH
- Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study.
- (2020) Erika Joelle Lampert et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer.
- (2020) Wilson H. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation
- (2020) Xinfang Yu et al. Journal of Hematology & Oncology
- Biomarker-Guided Development of DNA Repair Inhibitors
- (2020) James M. Cleary et al. MOLECULAR CELL
- ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
- (2020) Audrey Laroche-Clary et al. Scientific Reports
- Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
- (2020) Ah-Rong Nam et al. Cancer Research and Treatment
- ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
- (2020) Hailong Sheng et al. Journal for ImmunoTherapy of Cancer
- Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
- (2020) Hannah L Smith et al. Cancers
- Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
- (2020) Charles R. Dunlop et al. BRITISH JOURNAL OF CANCER
- A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
- (2020) Amit M. Oza et al. CLINICAL CANCER RESEARCH
- Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
- (2020) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
- (2020) Hyoung Kim et al. Nature Communications
- Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
- (2020) Dong-Hyeon Ha et al. Scientific Reports
- DNA Replication Stress and Chromosomal Instability: Dangerous Liaisons
- (2020) Therese Wilhelm et al. Genes
- Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability
- (2020) Sumeet Nayak et al. Science Advances
- Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cance
- (2020) Tzu-Ting Huang et al. CANCER RESEARCH
- A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
- (2020) Andrea Ghelli Luserna di Rorà et al. Journal of Hematology & Oncology
- Exploiting Replication Stress as a Novel Therapeutic Intervention
- (2020) Jeffrey C Martin et al. MOLECULAR CANCER RESEARCH
- CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress
- (2020) Feng Li et al. MOLECULAR CELL
- First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
- (2020) Timothy A. Yap et al. Cancer Discovery
- Harnessing DNA Replication Stress for Novel Cancer Therapy
- (2020) Huanbo Zhu et al. Genes
- SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
- (2020) Claudia Winkler et al. BRITISH JOURNAL OF CANCER
- Synergistic Targeting of CHK1 and mTOR in MYC-driven tumors
- (2020) Xiaoxue Song et al. CARCINOGENESIS
- PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
- (2020) Patrycja Gralewska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
- (2019) Yihan Peng et al. Nature Communications
- Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
- (2019) Amirali B. Bukhari et al. JOURNAL OF CLINICAL INVESTIGATION
- Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck
- (2019) Jong Woo Lee et al. CLINICAL CANCER RESEARCH
- DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
- (2019) Nisha Pillay et al. CANCER CELL
- Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress
- (2019) Lucy A. Young et al. CANCER RESEARCH
- A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
- (2019) Elizabeth Ruth Plummer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
- (2019) Udai Banerji et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA damage response inhibitor combinations exert synergistic antitumor activity in aggressive B cell lymphomas
- (2019) Valentina Restelli et al. MOLECULAR CANCER THERAPEUTICS
- Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
- (2019) Junko Murai et al. PHARMACOLOGY & THERAPEUTICS
- Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis
- (2019) Wenxiu Qi et al. BIOCHEMICAL PHARMACOLOGY
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
- (2019) Yong Fang et al. CANCER CELL
- Bromodomain and Extraterminal Domain Inhibition Synergizes with WEE1‐Inhibitor AZD1775 Effect by Impairing Non‐Homologous End Joining and Enhancing DNA Damage in Non‐Small Cell Lung Cancer
- (2019) Yuta Takashima et al. INTERNATIONAL JOURNAL OF CANCER
- Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition
- (2019) Priya Patel et al. OncoImmunology
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
- (2019) Kalindi Parmar et al. CLINICAL CANCER RESEARCH
- Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
- (2019) Triparna Sen et al. Journal of Thoracic Oncology
- Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition‐mediated genomic instability, inflammatory signaling and cytotoxicity in BRCA2‐deficient cancer cells
- (2019) Pepijn M. Schoonen et al. Molecular Oncology
- ATR inhibition sensitizes HPV− and HPV+ head and neck squamous cell carcinoma to cisplatin
- (2019) Brandon C. Leonard et al. ORAL ONCOLOGY
- Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer
- (2019) Nazareth et al. Cancers
- 450PDA phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)
- (2019) M Dillon et al. ANNALS OF ONCOLOGY
- Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition
- (2019) Cody W. Lewis et al. CANCER RESEARCH
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
- (2019) Kyle C. Cuneo et al. JOURNAL OF CLINICAL ONCOLOGY
- WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
- (2019) Tatiana N. Moiseeva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
- (2019) Ghelli Luserna Di Rorà et al. Cancers
- WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage
- (2019) Mathilde Rikje Willemijn de Jong et al. Cancers
- Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells
- (2019) Hitomi Nojima et al. EXPERIMENTAL CELL RESEARCH
- Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
- (2019) Christopher L. Heidler et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
- (2019) Karine Flem-Karlsen et al. MOLECULAR CANCER THERAPEUTICS
- Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
- (2018) A Italiano et al. ANNALS OF ONCOLOGY
- From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
- (2018) Kent W. Mouw et al. BRITISH JOURNAL OF CANCER
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma
- (2018) Qi Shi et al. CANCER LETTERS
- Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine
- (2018) Siang-Boon Koh et al. CANCER RESEARCH
- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
- (2018) Eduardo Méndez et al. CLINICAL CANCER RESEARCH
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
- (2018) Anish Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- The ATR Inhibitor AZD6738 Synergizes with GemcitabineIn VitroandIn Vivoto Induce Pancreatic Ductal Adenocarcinoma Regression
- (2018) Yann Wallez et al. MOLECULAR CANCER THERAPEUTICS
- BRD4 facilitates replication stress-induced DNA damage response
- (2018) Jingwen Zhang et al. ONCOGENE
- Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP-E2F1-DNA damage response pathway axis
- (2018) Yusuke Oku et al. FEBS Open Bio
- AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
- (2018) Xiangbing Meng et al. Cancers
- Abstract 2586: PI3K/AKT signaling pathway is transcriptionally elevated in prexasertib-resistant TNBC PDX models
- (2018) Yan Ding et al. CANCER RESEARCH
- Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers
- (2018) Matthew G. Krebs et al. CANCER RESEARCH
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
- (2018) Hongwei Liao et al. EMBO REPORTS
- Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress
- (2018) Morgane Macheret et al. NATURE
- Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids
- (2018) Sarah J. Hill et al. Cancer Discovery
- The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
- (2018) Fiona Middleton et al. Cancers
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe
- (2018) Nicholas Warren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
- (2017) Tamara B. Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers
- (2017) Amy Dréan et al. MOLECULAR CANCER THERAPEUTICS
- AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
- (2017) Ahrum Min et al. MOLECULAR CANCER THERAPEUTICS
- The essential kinase ATR: ensuring faithful duplication of a challenging genome
- (2017) Joshua C. Saldivar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine
- (2017) Shuang Liu et al. ONCOLOGY REPORTS
- A mitosis-specific and R loop–driven ATR pathway promotes faithful chromosome segregation
- (2017) Lilian Kabeche et al. SCIENCE
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
- (2017) Ethan Brill et al. Oncotarget
- WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
- (2017) Hongping Zheng et al. Scientific Reports
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress
- (2016) Kyle C. Cuneo et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
- (2016) Giorgio Scagliotti et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
- (2016) David Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
- (2016) Ankita Jhuraney et al. MOLECULAR CANCER THERAPEUTICS
- Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
- (2016) Magnus T. Dillon et al. MOLECULAR CANCER THERAPEUTICS
- BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells
- (2016) S V Muralidharan et al. ONCOGENE
- Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
- (2016) Emiliano Calvo et al. ONCOLOGY
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
- (2016) Chris T. Williamson et al. Nature Communications
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
- (2016) Katharina I. Deeg et al. Frontiers in Oncology
- Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors
- (2015) Toshihiko Doi et al. ANTI-CANCER DRUGS
- Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
- (2015) Sophia X. Pfister et al. CANCER CELL
- Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
- (2015) Guan Wang et al. CANCER LETTERS
- Molecular Pathways: Targeting ATR in Cancer Therapy
- (2015) L. M. Karnitz et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
- (2015) M. Aarts et al. MOLECULAR CANCER THERAPEUTICS
- LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
- (2015) C. King et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Exploiting replicative stress to treat cancer
- (2015) Matthias Dobbelstein et al. NATURE REVIEWS DRUG DISCOVERY
- Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
- (2015) R. L. Flynn et al. SCIENCE
- Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
- (2015) F. Cottini et al. Cancer Discovery
- Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair
- (2015) Tasneem Kausar et al. NEOPLASIA
- Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
- (2015) Amy B. Hall et al. Oncotarget
- Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
- (2015) Venkatasubbaiah A. Venkatesha et al. NEOPLASIA
- Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells
- (2014) William N Pappano et al. BMC CANCER
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
- (2014) L Zhou et al. LEUKEMIA
- Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
- (2014) A. A. Osman et al. MOLECULAR CANCER THERAPEUTICS
- Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress
- (2014) Apolinar Maya-Mendoza et al. Molecular Oncology
- RASSF1A–LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2
- (2014) Dafni-Eleftheria Pefani et al. NATURE CELL BIOLOGY
- Haploinsufficiency of an RB-E2F1-Condensin II Complex Leads to Aberrant Replication and Aneuploidy
- (2014) C. H. Coschi et al. Cancer Discovery
- Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
- (2013) Ryan Montano et al. BMC CANCER
- Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
- (2013) Takashi Seto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
- (2013) C. J. Huntoon et al. CANCER RESEARCH
- Identification of Preferred Chemotherapeutics for Combining with aCHK1Inhibitor
- (2013) Yang Xiao et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality
- (2013) A. A. Van Linden et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
- (2013) A. D. Guertin et al. MOLECULAR CANCER THERAPEUTICS
- BAF complexes facilitate decatenation of DNA by topoisomerase IIα
- (2013) Emily C. Dykhuizen et al. NATURE
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
- (2013) Jenny M. Kreahling et al. PLoS One
- Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation
- (2013) WooKee Min et al. Nature Communications
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption
- (2012) H. Beck et al. MOLECULAR AND CELLULAR BIOLOGY
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes
- (2011) Christopher M. Heaphy et al. AMERICAN JOURNAL OF PATHOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
- (2011) K. A. Bridges et al. CLINICAL CANCER RESEARCH
- Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
- (2011) Raquel Domínguez-Kelly et al. JOURNAL OF CELL BIOLOGY
- MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
- (2011) J. M. Kreahling et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
- (2011) R. Montano et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
- (2011) Matilde Murga et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
- (2010) Hiroshi Hirai et al. CANCER BIOLOGY & THERAPY
- Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair
- (2010) Meredith A. Morgan et al. CANCER RESEARCH
- Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
- (2009) L. A. Parsels et al. MOLECULAR CANCER THERAPEUTICS
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- An Oncogene-Induced DNA Damage Model for Cancer Development
- (2008) T. D. Halazonetis et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now